In the thymus, based on the reactivity of their T-cell receptor with self-MHC and antigenic peptides, developing immature T-cells undergo positive and negative selection. Cells recognising self-peptides and MHC with high affinity are considered autoreactive, and thus potentially harmful, and are eliminated by induction of apoptotic cell death. Thymic negative selection is, however, only incomplete and autoreactive T-cells escape into the periphery. It is not the presence of autoreactive mature T-and B-lymphocytes as the underlying cause of tissue destruction and development of autoimmune diseases, but their uncontrolled and excessive clonal expansion upon activation by self-antigen. Thus, potent regulatory mechanisms must keep these autoreactive cells under control to avoid their inappropriate activation. Recent evidence indicates that death receptors of the tumour necrosis factor receptor family play a central role in mediating antigen receptor-induced suicide of autoreactive T-lymphocytes. Defects in these apoptosis-inducing regulatory mechanisms may result in the development of autoimmune diseases. Therefore, enhancing the cell's own suicide program, offers a most attractive therapeutic target for the treatment of autoimmune diseases.
Introduction
Many typical infectious diseases, such as those initiated and mediated by invading and parasiting viruses, bacteria and other pathogens, can successfully be fought by activating the body's own defence mechanism, the immune system, as by vaccination for example. In autoimmune diseases, the enemy lies within. It is the uncontrolled action of this otherwise mostly beneficial and protective immune system, that causes a variety of different forms of self-destruction. The decision criteria that make the glorious defender of our body a corrupt betrayer have been the topic of extensive research. Whereas we currently understand many aspects of autoimmune disease development, the essential breakthroughs in the treatment of autoimmune diseases are still awaiting, and few successful therapeutic interventions are currently established. Thus, novel and potentially also This review will focus on a novel target of autoimmune therapy: the T-lymphocyte's own suicide program. Besides its novelty, it represents the logical consequence of our increasing knowledge of how immune responses are normally regulated and terminated: the removal of undesired cells by apoptotic cell death. To estimate the potential role and usefulness of this therapeutic target, common aspects of all autoimmune diseases and the cellular and molecular bases of their destructive forces should first be discussed.
In general, all autoimmune diseases result in the destruction of tissues and cells that are vital for the functioning of the body (reviewed in [1]). A major aspect in this process is the crucial involvement of the immune system and the specific recognition of self-antigens by B-and T-cells. This specific recognition will initiate a rather uncontrolled immune response against self-antigens. Cells expressing these structures may either be direct targets of cell-mediated cytotoxicity or of auto-antibodies. This specific recognition of self-antigen initiating an autoimmune response appears to be a key element in the development of autoimmune diseases, and is reflected by the fact that many autoimmune diseases have a genetic predisposition, i.e. susceptibility to the disease can be correlated with certain HLA phenotypes [2] . Yet, although the presence of autoreactive T-cells and B-cells can be easily demonstrated in most individuals, autoimmune tissue destruction, with subsequent clinical onset of an autoimmune disorder, is a rare event. This suggests that efficient control mechanisms exist to prevent autoreactive lymphocytes from being activated and mounting a destructive immune response against self.
What are these control mechanisms, how do they work, why do they fail sometimes? Can they be targeted for efficient treatment of autoimmune diseases? The answers to these questions may well form the basis for the development of novel therapies.
The T-cell as a major target of autoimmune disease treatment
Extensive research has been focussing on the role of T-cells in the development of autoimmune disease [3] [4] [5] . T-cells specifically recognise antigen with their T-cell receptors. Their activation leads to the development of effector functions. In the case of autoreactive T-cells, this may result in cell-mediated cytotoxicity and subsequent tissue destruction. In addition, the helper function for B-cells enhances production of auto-antibodies and further tissue destruction. Although B-cells can recognise certain antigens directly via the B-cell receptor, the recognition of many antigens by B-cells requires T-cell help (costimulation and cytokines) for successful antibody production and immunoglobulin class switch. Thus, irrespective of the effector mechanisms involved in the autoimmune destruction process, the T-cell is an important orchestrating cell type of the immune system, and thus represents a major target for the modulation of most immune responses, including those involved in autoimmune diseases. Therefore, a successful therapy should be aimed at regulating, eliminating or suppressing these autoreactive and disease promoting T-cells.
During their development in the thymus, immature lymphocytes will acquire a T-cell receptor with a defined, but random, specificity. Upon further intrathymic differentiation, those immature thymocytes recognising self-antigens in the context of MHC (HLA) molecules with high affinity are eliminated through induction of apoptosis. As evidenced by the frequent detection of potentially autoreactive T-cells in peripheral blood this negative selection of thymocytes is not complete. Some potentially autoreactive T-cells may escape this central deletion and migrate to peripheral lymphoid organs. However, autoreactive T-cells appear not only to escape from thymic negative selection in patients suffering from autoimmune disease, but can also be detected in healthy individuals (reviewed in [5] Figure 1 ).
CD95 and TNF receptor I and II belong to the family of TNF-/nerve growth factor receptor-like homologous molecules, all intimately involved in either mediating apoptosis or survival. CD95 and TNF receptors appear to be the most relevant apoptosis-inducing receptors in T-cell regulation, whereas other members of this family, also capable of activating the death machinery (such as death receptor (DR) 3, 4 and 5), are probably less important [37] .
Autoreactive T-cells that have escaped thymic negative selection may fail to encounter antigen for the duration of their life, due to inaccessibility of the antigen (e.g., proteins with highly tissue specific expression, such as insulin), and may persist in a resting state until antigen may be uncovered (e.g., after tissue damage) [38] . In contrast, some autoreactive T-cells may constantly be exposed to self-antigens presented by professional or non-professional antigen-presenting cells. Whereas autoreactive T-cells may be relatively frequent, the development of autoimmune pathologies is still a remarkably rare event. It must be questioned as to what prevents these autoreactive T-cells from causing autoimmune disorders. There is increasing evidence that the same mechanisms that control the extent of an immune response, also regulate autoreactive T-cells. Autoreactive T-cells that frequently encounter their specific (self-) antigen will most likely undergo AICD. Whereas it is not easy to quantify this mechanism in a healthy individual, we may estimate the importance of this regulatory event by the analysis of experimental autoimmune disease models and autoimmune disease patients. Thus, it has been found that mice lacking functional CD95 (lpr) and CD95L (gld) develop a severe lupus-like autoimmune disease, with lymphoadenopathy and high numbers of autoreactive T and B cells [33, 39] . The fact that lack of CD95/CD95L-mediated suicide is responsible for this spontaneous development of autoimmune disease is demonstrated by the observation that transgenic expression of functional CD95 can reverse autoimmunity in lpr mice [40, 41] . Similarly, different studies have shown that many patients with autoimmune diseases have genetic defects in either the CD95, or the CD95L gene. Heterozygous mutations result in a mild form; homozygous mutations in the CD95 or CD95L locus lead to a more severe form of the disease [42] [43] [44] . 
Regulation of AICD, CD95-and TNF receptor-induced apoptosis
It appears obvious that CD95-and TNF receptorinduced apoptosis has to be a rather tightly regulated event. In particular, TNF receptor I and II are ubiquitously expressed. Therefore, low levels of inflammation would cause significant tissue damage due to systemically released TNF-α. Similarly, in the absence of negative regulatory components in the CD95 signalling cascade, activated B-and T-lymphocytes would be immediately eliminated by CD95-induced apoptosis, and our body would become defenceless because of immune incompetence. Therefore, efficient immune homeostasis requires a fine-tuned balance between inhibition of apoptosis and development of immune effector functions on one hand, and induction of apoptosis, inhibition of tissue damage and development of autoimmune diseases on the other. What is the nature of these negative regulatory elements that allow this fine-tuning of immune responses? Could their inappropriate expression represent initiation for the development of autoimmune disease? Increasing evidence indicates that similar mechanisms regulate normal T-cell homeostasis and autoimmune T-cells, with the slight, but significant difference that inhibitors of apoptosis appear not to be appropriately down-modulated during the onset of autoimmune disorders, thus leading to an extended expansion of autoreactive T-cells. Therefore, the modulation of expression and/or activity of these inhibitors offers an attractive potential target for the treatment of T-cellmediated autoimmune diseases.
Many inhibitors of apoptosis, and more specifically of TNF receptor -and CD95-induced apoptosis, have been identified. Whereas the protective effect of Bcl-2 on CD95-induced apoptosis and AICD is still controversial [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] , both Bcl-2 and Bcl-x L certainly have an important function in maintaining the survival of developing T and B-lymphocytes and in the prevention of apoptosis induced by other agents in many different cell types. Their role in development of autoimmunity has not been fully explored, but circumstantial evidence suggests, at best, a limited role in these processes, since transgenic overexpression of Bcl-2 and Bcl-x L protects T-cells from dexamethasone and radiation-induced apoptosis, whereas AICD in vitro and in vivo remains normal [50, 55] . However, development of autoimmunity in lpr mice appears to be potentiated by transgenic overexpression of Bcl-2 [56, 57] . This indicates that enhanced survival of immature T-cells by Bcl-2 overexpression may result in elevated numbers of mature potentially autoreactive T-cells, unless they are eliminated by AICD.
Hence, inhibitory molecules preventing induction of apoptotic pathways operative in T-cells, such as CD95 and TNF-receptor-induced apoptosis, may thus represent prime candidates to cause inappropriate survival and expansion of autoreactive T-cells in the periphery. Of particular interest are the recently identified FAP-1 (Fas-associated protein-1) and FLIP (Flice-like inhibitory protein). FAP-1 has been identified by its association with the intracellular domain of CD95 [58] . Interestingly, this domain, consisting of the last 15 amino acids at the N-terminal end, has been found to exhibit a regulatory function [59] . Whereas CD95 ligation does not always trigger apoptosis in certain cell types, due to specific inhibition of CD95 signalling pathways, truncation of this regulatory domain leads to accelerated apoptosis upon CD95 crosslinking. Therefore, this domain may interact with potential inhibitors of the CD95 signalling cascade. Indeed, Sato and colleagues have shown that overexpression of FAP-1 in Jurkat cells reduces apoptosis upon CD95 ligation [58] . Up to now, it is unclear whether FAP-1 inhibits via sterical hindrance of CD95 trimerisation and assembly of the signalling complex (FAP-1 has a molecular weight of approx. 200 kd), or through its tyrosine phosphatase activity [58] .
One of the first events in the CD95 signalling cascade is the recruitment of FADD (Fas-associated death domain) and caspase 8 (a cysteine protease) to the receptor and the proteolytic processing of caspase 8 to its mature form [60] . Cellular FLIPs are molecules with strong sequence homology to caspase 8, which appear to compete for FADD binding and therefore specifically block CD95 and TNF receptor I signalling and apoptosis at a very early stage [61, 62] . Thus, FLIP would fulfil the above described requirements for a specific regulator of normal immune homeostasis and autoimmunity. Indeed, it has been found that IL-2, which promotes sensitivity to AICD in T-cells, also down-modulates FLIP and FAP-1 expression [63, 64] . Alternatively, other molecules that may affect FLIP activity (e.g., by regulating its expression or recruitment to the receptor) could be responsible for the reduced sensitivity to AICD in T-cells [65] . Regardless of the identity and relative importance of these inhibitors, they appear to have one thing in common, which may allow to target efficiently these molecules. The relevant inhibitors of CD95-and TNF receptorinduced apoptosis must have a rather limited half-life, since cells which are resistant to TNF-α or CD95 ligation (e.g. L929 cells and day 2 T-cells blasts, respectively) become sensitive to apoptosis induction after treatment with low concentrations of RNA and protein synthesis inhibitors. Since this effect is rather well distributed among different cell types, it is suggested that very few inhibitory molecules, ubiquitously expressed, may be responsible for the resistance of resting (or autoimmune) T-cells to TNF receptor-or CD95-induced cell death. Thus, this 'central blocker' of death receptor-induced apoptosis offers a prime target for drug development (see Figure 2 ).
Bisindolylmaleimide VIII: a novel and prototypic drug for the treatment of autoimmune diseases
A significant step towards specific inhibition of such a 'central blocker' was achieved in a recent study by Zhou and co-workers [66] . They have noticed that the protein kinase C (PKC) inhibitor, bisindolylmaleimide VIII (Bis VIII) (see Figure 3) sensitises different tumour lines, as well as primary T-cell lines for CD95-and TNF receptor-induced apoptosis. This observation had been made previously by other research groups [67] . However, it was the accomplishment of Zhou and colleagues that demonstrated that inhibition of this 'central blocker' of death receptor-induced apoptosis can inhibit development of autoimmune diseases in vivo. Thus, in two experimental models of autoimmune disease, EAE and adjuvant-induced arthritis, disease progression and severity were strongly reduced by the repeated administration of Bis VIII. The attenuation of autoimmune disease development is most likely mediated by enhancing the T-cell's own suicide program (AICD), since death, and therefore inhibition of the immune response, are restricted to antigen-specific T-cells [66] . How does Bis VIII work? Will the understanding of its mode of action help us to identify the relevant targets for the treatment of autoimmune diseases? Whereas Bis VIII has been described so far as a potent inhibitor of PKC activation, the study by Zhou et al. indicates that the death-receptor sensitising activity of Bis VIII may not necessarily be related to PKC inactivation. Among different PKC inhibitors, only few were capable of sensitising target cells for CD95-induced apoptosis. Interestingly, however, all of those that exhibit a CD95 sensitising activity were bisindolylmaleimide derivatives [66] . Different explanations may account for this selective acceleration of CD95-induced apoptosis by bisindolylmaleimides: either bisindolylmaleimides have additional, yet unidentified, targets (unrelated to PKC) responsible for inhibition of death receptor induced apoptosis; alternatively, these drugs act more efficiently on distinct members of the large number of different PKCs. PKCs are a family of serine/threonine protein kinases, with different requirements for Ca 2+ and activation by diacylglycerol. Certain isoforms have been implicated in distinct signalling pathways. Similarly, they appear to be differentially expressed in different tissues and cell types [68] . Thus, it is tempting to speculate that inhibitory effects on death receptorinduced apoptosis are mediated by distinct PKC isoforms which are efficiently antagonised by Bis VIII or related drugs. In favour of this hypothesis is the observation that phorbolmyristate acetate (PMA), a synthetic analogue of diacylglycerol, activates different PKCs and also attenuates anti-CD95-induced apoptosis in lymphoid tumours (see [69] and own unpublished results). However, PMA also inhibits UV-induced apoptosis in this cell type (T Brunner, unpublished results). By contrast, Bis VIII activity appears to be restricted to death receptor-induced apoptosis, and does not affect dexamethasone-and γ-radiation-mediated death [66] . Therefore, the anti-apoptotic effect of PMA and the pro-apoptotic effect of Bis VIII could be unrelated. Alternatively, PMA could affect the CD95/CD95L-mediated signalling cascade of UV-induced apoptosis [70, 71] . Thus, UV radiation induces expression of CD95L and subsequent apoptosis.
To date, no satisfying explanations for the activity of Bis VIII on AICD has been found. However, the hypothesis that distinct isoforms of PKC may be blocked by Bis VIII is attractive for several reasons. PKC has been shown to activate the transcription factor NFκB [68] . Similarly, many different stimuli, including TCR ligation and TNF-α, can activate PKC and induce resistance to subsequent CD95-and TNF receptor-induced apoptosis, respectively [72] [73] [74] [75] . In particular, the activation of NFκB appears to be an important step for the activation of genes intimately involved in mediating cell survival [74] [75] [76] [77] . One family of NFκB-regulated target genes are the so-called inhibitors of apoptosis (IAPs), i.e., cellularly or virally encoded proteins which efficiently block apoptosis in response to different stimuli, as well as to TNF-α and CD95L [78] [79] [80] [81] . Most signalling pathways inducing apoptosis involve the activation of a family of cysteine proteases (caspases) that either cleave additional immature forms of other family members, thus activating a cascade, or cleave proteins involved in cell structure or DNA replication [82] . Interestingly, IAPs can block apoptosis at the level of caspase activation through direct interaction with these caspases. Thus, c-IAP-1 and c-IAP-2 can bind and inactivate the two effector caspases, 3 and 7 [83] . By blocking NFκB activation, Bis VIII may regulate apoptosis through inhibition of IAP gene transcription, thus facilitating caspase activation. Recently, Wang and colleagues [77] have shown that NFκB induces expression and activation of TRAF1, TRAF2 (two signalling molecules of TNF receptor I and II) and c-IAP-1 and -2, and that these molecules are capable of blocking TNF-α-induced apoptosis at the level of caspase 8 activation. Since caspase 8 is the most proximal caspase in the TNF receptor I and CD95 signalling cascade, it is suggested that these molecules directly act on the activation of this caspase, and that CD95-induced apoptosis could also be blocked by this mechanism (see Figure 4) .
Several other mechanisms may account for the effect of Bis VIII on AICD and amelioration of autoimmunity in vivo. Whereas the identification of the signalling events that are affected by Bis VIII is mandatory for the development of more specific therapeutic approaches, the results obtained so far with this prototypical drug are highly encouraging for future development of similar drugs and strategies. Analogous to the process of tolerance induction using (auto-) antigenic peptides, the initial trigger leading to this functional unresponsiveness remains the antigen-specific activation of the T-cell. The specific activation of these sensitised T-cells leads to the expression of CD95 and CD95L and subsequent apoptosis. The auto-antigen involved in the disease does not have to be identified. Thus, the concept of enhancing the T-cells' own suicide program, which already exists but is impaired in autoimmune disease, may be an effective treatment of autoimmune diseases [84] . Zhou and colleagues [66] have demonstrated the beneficial effect of Bis VIII on two different experimental models of CD4 + T-cell-mediated autoimmune diseases. Although it still remains to be formally demonstrated, Bis VIII may also ameliorate immunopathologies that involve cytoxic CD8 + T-cells, since TNF-α-induced apoptosis, an essential components of AICD in CD8 + T-cells [35, 36] , is also enhanced. In addition, other diseases that are also mediated by an overly aggressive T-cell-mediated immune response (e.g. graft-versus-host disease, allograft rejection, inflammatory bowel disease), might be effectively targeted by Bis VIII.
Therapies aiming at enhancing the death receptormediated suicide of autoreactive lymphocytes may not necessarily depend on the development of apoptosis-sensitising drugs, such as Bis VIII. We and others have noticed that polarised T-cells show differential sensitivity to AICD [85, 86] . CD4 + T-lymphocytes may not only differentiate into functional subsets producing distinct cytokines, but may also develop differential sensitivity towards CD95 ligation. Thus, T-cells differentiated into the T-helper (TH) 1 phenotype produce interferon-γ (IFN-γ) and interleukin-2 (IL-2) and show enhanced sensitivity towards AICD and CD95, whereas TH2 cells express IL-4, IL-5, IL-10 and show relative resistance to AICD [85, 86] . The enhanced resistance of TH2 cells over TH1 is most likely mediated by the differentiationinduced expression of FAP-1, which inhibits CD95 signalling [86] . Similarly, other cytokines, such as IFN-γ and IL-2, have been shown to enhance the sensitivity of T-cells for AICD and CD95-mediated apoptosis. Most likely, IL-2 does so by down-modulating FAP-1 and FLIP expression [63, 64] . Therapies designed to modulate the immune response by specifically blocking certain polarising cytokines may therefore provide results similar to those achieved by Bis VIII. However, such strategies, aiming at the differentiation of CD4 + T-cells towards AICD-sensitive TH1 cells, will also have to deal with problematic side effect of enhanced cytotoxicity and therefore tissue destruction mediated by TH1 cells.
Whereas the identification of the molecular targets of Bis VIII will allow the design of more specific drugs to be used in the treatment of autoimmune diseases, specific inhibition of known anti-apoptotic molecules has been already successfully applied in experimental in vitro and in vivo systems. Yanagisawa and colleagues have identified the amino acid sequence in the cytoplasmic tail of CD95 responsible for the interaction with FAP-1 [87] . Administration of a synthetic tripeptide, corresponding to this sequence, to FAP-1 expressing colon carcinoma cell lines, rendered them sensitive to CD95-induced apoptosis. Similarly, down-modulation of the anti-apoptotic 14:18 chromosome breakpoint gene product Bcr-Abl by antisense oligonucleotides, efficiently sensitised otherwise resistant tumour cells to CD95 ligation [88] .
In vivo targeting of Bcl-2 with antisense oligonucleotides has been already successfully used to support chemotherapy of human malignant tumours transferred to SCID mice [89] .
We must, however, be cautious: since Bis VIII sensitises all cells, not only autoreactive T-cells, the humoral and cellular immune responses against invasion could also be impaired. Thus, particular caution must be taken during such treatment with Bis VIII-like drugs to avoid uncontrolled infections with opportunistic germs and viruses. Similarly, Bis VIII will probably also sensitise tissue cells for TNF-α and CD95L-induced apoptosis. Thus, premature loss of intestinal epithelial cells or hepatocytes due to insufficient removal of activated T-cells may result in severe side effects [90, 91] . An important caveat to the universal use of Bis VIII and similarly acting substances is the recent finding that many non-lymphoid tumours can express CD95L on their cell surface (reviewed in [92] ) Although it is not completely clear as to the extent CD95L represents a tumour escape mechanism, Bis VIII may sensitise tumour-infiltrating T-cells to CD95L-induced apoptosis, and thus prevent an efficient antitumour immune response. In addition, the tumour would most likely survive this scenario, since many tumour cells have down-modulated CD95 on their cell surface, and are thus insensitive.
Other limitations for the use of Bis VIII-like drugs may be given by the molecular defects inherent to some of the autoimmune diseases to be treated. Figure 5 ).
Conclusion and expert opinion
Increasing evidence indicates that uncompromised death receptor-mediated suicide is crucial for the control of normal immune homeostasis and autoimmunity. The inappropriate survival of autoreactive T-cells due to resistance to this suicide program represents the most likely underlying cause of many autoimmune diseases. Therefore, molecules that regulate death receptor-mediated apoptosis are important targets for specific therapeutic approaches and the development of drugs aimed at reducing development of autoimmunity. From this perspective, Bis VIII represents a prototypic drug that shows very promising effects on the treatment of certain experimental autoimmune disease models and therefore strongly encourages further research on the specific activation of the cell's inherent suicide program. The beneficial effects of Bis VIII on autoimmune diseases may currently be overestimated, and potential pitfalls and side effects may become evident only at a later stage of research. However, the concept of enhancing the self-programmed demise of autoreactive T-cells may lead to more specific and more successful drugs and therapies for the treatment of autoimmunity. 
